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Abstract
Introduction: The effects of hydroxyethyl starch (HES) on patient-centered outcome measures have not been fully
described in patients with severe sepsis. We assessed health-related quality of life (HRQoL) and the occurrence of
pruritus in patients with severe sepsis randomized to resuscitation with HES 130/0.42 or Ringer’s acetate.
Methods: We did post hoc analyses of the Danish survivors (n = 295) of the 6S trial using mailed questionnaires
on self-perceived HRQoL (Short Form (SF) - 36) and pruritus.
Results: Median 14 months (interquartile range 10 to 18) after randomization, 182 (61%) and 185 (62%) completed
questionnaires were obtained for the assessment of HRQoL and pruritus, respectively. Responders were older than
nonresponders, but characteristics at randomization of the responders in the HES vs. Ringer’s groups were
comparable. At follow-up, the patients in the HES group had lower mental component summary scores than those
in the Ringer’s group (median 45 (interquartile range 36 to 55) vs. 53 (39 to 60), P = 0.01). The group differences
were mainly in the scales of vitality and mental health. There was no difference in the physical component
summary scores between groups, but patients in the HES group scored worse in bodily pain. Forty-nine percent of
patients allocated to HES had experienced pruritus at any time after ICU discharge compared to 43% of those
allocated to Ringer’s (relative risk 1.13, 95% confidence interval 0.83 to 1.55, P = 0.43).
Conclusions: At long-term follow-up patients with severe sepsis assigned to resuscitation with HES 130/0.42 had
worse self-perceived HRQoL than those assigned to Ringer’s acetate whereas there were no statistically significant
differences in the occurrence of pruritus.
Introduction
Hydroxyethyl starch (HES) has been one of the most fre-
quently used fluids for resuscitation in intensive care
units (ICUs) worldwide [1]. However, recent trials of
HES 130/0.38 to 0.45 (molecular weight/substitution
grade) have shown increased frequency of adverse events
and use of renal replacement therapy and blood products
in general ICU patients in addition to increased mortality
in patients with severe sepsis [2,3]. Moreover, HES treat-
ment has been shown to cause pruritus described as
dose-dependent, delayed in onset and persistent [4].
Studies report pruritus occurrence in none to 55% of
patients [5-12] and it is controversial if HES 130/0.38 to
0.45 causes less pruritus than the HES solutions with
higher molecular weight and substitution grade [10]. The
effects of HES 130/0.38 to 0.45 on patient-centered out-
come measures have not been fully described in patients
with severe sepsis. The purpose of this study was to
assess self-perceived health-related quality of life
(HRQoL), being one of the most important indicators of
health care [13] and the occurrence of pruritus in long-
term survivors of the Scandinavian Starch for Severe
Sepsis/Septic Shock (6S) trial [3]. We hypothesized, that
the HES group would have worse HRQoL and pruritus
than those in the Ringers group.* Correspondence: snajper2@yahoo.co.uk1Department of Anaesthesia and Intensive Care, Herning Hospital, Gl.
Landevej 61, 7400 Herning, Denmark
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Materials and methods
Participants
The study population comprised the Danish survivors of
the 6S trial as identified in the National Patient Registry.
The 6S trial was investigator-initiated, multicenter,
blinded, stratified, parallel-grouped using a computer-gen-
erated allocation sequence and centralized, blinded rando-
mization. The inclusion and exclusion criteria are given in
Additional file 1 and the CONSORT diagram of the
screening, randomization and the 90-day follow-up pro-
cess appears in the original publication and in the study
protocol [3,14]. The participants in the 6S trial were ran-
domly allocated to fluid resuscitation in the trial ICUs
between December 2009 and November 2011 using either
6% HES 130/0.42 in Ringer’s acetate (Tetraspan 6%, B
Braun Medical, Melsungen, Germany) or Ringer’s acetate
(Sterofundin ISO, B Braun Medical). The unblinding of
the trial occurred on 24 March 2012.
In March 2012, printed copies of the short form (SF)-36
and a self-composed pruritus questionnaire were sent to
all the Danish survivors together with a letter explaining
the purpose of the follow-up study. Nonresponders were
contacted by telephone in May 2012. Consent was
obtained at the inclusion in the 6S trial, and the post hoc
analyses and renewed contact with the patients were
approved by the Danish Medicines Agency and the Ethics
Committee for the Capital Region of Denmark. At the
time of contact, none of the patients knew the results of
the 6S trial or which trial fluid they had received.
Assessment of HRQoL
The SF-36 comprises three levels: items (questions), scales
scoring the items and main summary scores aggregating
the scales - the physical and mental component summary
(PCS and MCS) scores. It is a self-administered question-
naire consisting of 36 items measuring eight scales of
health: physical functioning (PF), role of limitations due to
physical health (RP), bodily pain (BP), general health per-
ceptions (GH), vitality (VT), social functioning (SF), role
of limitations due to emotional problems (RE), and mental
health (MH). Since its creation in the early 1990s the
questionnaire has been used and validated in different
clinical settings including ICU patients [15-17].
We used the Danish version of the questionnaire. To
adapt the original (English, USA) version of SF-36, all
the items have been translated as described by the Inter-
national Quality of Life Assessment protocol [18] and
validated in accordance with the local characteristics of
the population [19,20].
Assessment of pruritus
Pruritus was assessed by a self-composed questionnaire
(see Additional file 1) including a visual analog scale
(VAS) to describe the intensity of pruritus. We asked
about the occurrence of pruritus in the past two days as
well as at any time after the index ICU admission,
actions taken to relieve pruritus, specifying the use of
ointments, tablets and contact to general practitioner,
dermatologist or other.
Statistical analyses
The investigator (PW) analyzing the data was blinded to
the assigned trial fluids. The predefined primary out-
come measures were the PCS and MCS scores for the
HRQoL part and any pruritus after ICU discharge (‘Yes’
in either question 1 or 2, see Additional file 1) for the
pruritus part. The secondary outcome measures were
the scale scores for the HRQoL part, pruritus in the last
48 hours, the severity of pruritus and actions taken
against pruritus.
SF-36 was scored according to the manual [21]. Three
different methods were applied to assess the influence
of missing data on the results: 1) a complete-case analy-
sis rejecting scales where any item was missing, 2) ana-
lyses of imputed data using missing data estimation
(MDE) software provided by Quality Metrics Inc. (Lin-
coln, RI, USA) and 3) two best/worst-case analyses
where missing answers in the HES group were set to
the worst possible answer and missing answers in the
Ringer’s group were set to the best possible answer and
vice versa. The latter analyses were done after unblind-
ing of the investigator performing the analyses.
All the obtained scores for the eight scales and PCS
and MCS scores were described as median values with
interquartile ranges (IQR) and compared between the
trial groups using the Mann-Whitney U test. The
response consistency index (RCI) was calculated to
assess the potential inconsistencies within the relevant
items of the SF-36. The scales were evaluated for inter-
nal consistency by Cronbach’s alpha coefficients and for
the discriminate validity between the mental and the
physical components.
To evaluate the occurrence of pruritus in total, we
described the percentage of affirmative answers in ques-
tions 1 and 2 of the questionnaire, while the severity
was assessed by the median scores on VAS and com-
pared between the treatment groups using the chi-
square test and Mann-Whitney U test, respectively. The
answers to questions concerning actions taken against
pruritus were described as percentages and compared
between groups using chi-square testing. The statistical
analyses were done using Health Outcomes Scoring
Software (Quality Metrics Inc.), SPSS Statistics version
20.0 (IBM, Armonk, NY, USA) and SAS 9.2 (SAS Insti-
tute Inc., Cary, NC, USA). P values < 0.05 were consid-
ered significant.
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Results
The inclusion process yielded 182 (HRQoL) and 185
(pruritus) valid responses from a total of 295 different
patients median 14 months (IQR 9 to 18) after randomiza-
tion. The response rates were 61% for HRQoL and 62% for
pruritus (Figure 1). The responders were older and more
had shock at randomization compared to the nonrespon-
ders (Table 1). Among the responders the baseline charac-
teristics at randomization and time to follow-up (Table 2)
were comparable between patients assigned to HES and
those assigned to Ringer’s.
Data quality
Completeness of data in SF-36, defined as completed
responses divided by the total possible number of
responses was 96%. In the cases of twenty patients, it was
impossible to calculate all the scales. All the obtained
responses were within range for the individual items.
Eighty-four percent of the responses were defined as con-
sistent using RCI, with a total of 30 questionnaires con-
taining items with sporadic inconsistencies (in one or two
questions). We were able to score all the scales in 90% of
the cases without using any imputation of missing data,
which increased to 97% after imputation of missing data.
The internal consistency of the items, defined by cor-
relation of 0.4 with their hypothesized scale was 100%.
The item MH4 ‘have you felt downhearted and blue’
correlated better (0.61) with VT than with its hypothe-
sized scale MH. All the other items showed highest cor-
relations with their designed scales. The reliability
estimates, defining the correlation grade, (with the
exception of PF) ranged from 0.83 (MH) to 0.89 (RP);
PF reached the value of 0.94.
Most of the questionnaires evaluating pruritus were
complete (0.5 to 11% missing answers), and there were
no inconsistencies within the questionnaires.
Health-related quality of life
The patients allocated to HES had significantly lower
MCS score, bodily pain, vitality, social function
and mental health than those allocated to Ringer’s
(Table 3). There were no statistical differences in PCS
scores between the intervention groups. Comparable
results were observed in the complete-case analyses
with the exception of social function (P = 0.07 without
imputation). The best/worst-case analyses did not
change the direction of the intervention effect, but
only mental health remained statistically different
when the missing values in the HES group were sub-
stituted with the best possible score and those in the
Ringer’s group the worst possible score (see Table S1
in Additional file 1).
705 Danish patients were included in the 6S-trial 
354 patients were assigned to HES 351 patients were assigned to Ringer’s Acetate 
212 died before 11th March 2012 
2 address  unknown 
195 died before 11th March 2012 
1 address  unknown 
140 survivors received questionnaires by mail 155 survivors received questionnaires by mail 
95 SF-36 questionnaires were analysed 
96 pruritus questionnaires were analysed 
87 SF-36 questionnaires were analysed 
89 pruritus questionnaires were analysed 
82 responded by mail 
16 responded by phone interview 
 
3 SF-36 questionnaires were unaswered 
2 pruritus questionnaires were unaswered 
75 responded by mail 
17 responded by phone interview 
 
5 SF-36 questionnaires were unaswered 
3 pruritus questionnaires were unaswered 
Figure 1 Flowchart of the data collection process. Reasons for nonresponding were as follows: eight were too sick to answer (four in each
group), six were unwilling to participate and for the remaining ninety-one patients our attempts to reach them by telephone were unsuccessful.
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Pruritus
There were no statistical significant differences between the
groups in the occurrence or severity of pruritus (Table 4).
More patients in the HES group had used ointments or
tablets against pruritus than those in the Ringer’s group
(Table 4). Seven patients (six in the Ringers group) indi-
cated that they had pruritus in the last 72 hours prior to
answering the questionnaire, but not before.
Discussion
In post hoc analyses of this multicenter, blinded, rando-
mized trial of fluid resuscitation in severe sepsis, HRQoL
at long-term follow-up was lower in patients allocated to
HES 130/0.42 compared to those allocated to Ringer’s
acetate. The differences in HRQoL were observed in the
MCS score, three scales describing the mental health and
in one scale describing the physical health of the patients.
To the best of our knowledge this is the first report
on HRQoL after fluid therapy with HES. We can only
speculate on the mechanisms by which HES adversely
affected HRQoL. As the patients allocated to HES had
more bleeding episodes, higher use of blood products
and renal replacement therapy and fewer days out of
hospital in the 90-day trial period after randomization,
all these factors may have contributed to lower HRQoL
compared with patients in the Ringer’s group [3]. In
addition, long-term toxic effects of HES deposited in
kidney, liver and bone marrow have been documented
[22-25]. HES does not seem to cross the intact blood-
brain barrier in animal models, however, it does accu-
mulate in the peripheral nerves [26,27]. These toxic
effects may affect the general health and thereby
HRQoL of the patients, but we do not have data to sub-
stantiate such effects in our patients.






Allocated to HES - n (%) 98 (52) 42 (40) 0.06
Age - years 66 (59-74) 56 (49-66) < 0.0001
Male gender - no. (%) 105 (55) 65 (62) 0.27
Included at university hospital - no. (%) 71 (37) 37 (35) 0.72
Surgery1 - no. (%)
Emergency 64 (34) 29 (28) 0.28
Elective 24 (13) 10 (10) 0.42
Source of sepsis2 - no. (%)
Lungs 80 (42) 59 (56) -
Abdomen 73 (38) 24 (23) -
Urinary tract 26 (14) 15 (14) -
Soft tissue 23 (12) 15 (14) -
Other 22 (12) 8 (8) -
SAPS II 49 (38-58) 47 (34-55) 0.16
SOFA score3 7 (5-9) 7 (5-9) 0.64
Shock4 - no. (%) 160 (84) 76 (72) 0.02
Acute kidney injury5 - no. (%) 71 (37) 34 (32) 0.39
Mechanical ventilation - no. (%) 98 (52) 59 (56) 0.45
Comorbidities
Diabetes mellitus - no. (%) 28 (15) 23 (22) 0.12
Arterial hypertension - no. (%) 81 (43) 33 (31) 0.06
Chronic renal disease6 - no. (%) 23 (13) 20 (21) 0.11
Hematological malignancy - no. (%) 15 (8) 3 (3) 0.08
Previous admission for - no. (%)
Heart failure or myocardial infarction 22 (12) 9 (9) 0.42
Stroke 13 (7) 11 (10) 0.27
Asthma or COPD 24 (13) 15 (14) 0.69
1Numbers are for patients who underwent surgery during the index hospitalization, but before randomization. 2Some patients had more than one source of
infection. The ‘other’ category included sepsis from a vascular catheter-related infection, meningitis, or endocarditis, as well as sepsis from unknown sources. 3The
SOFA scoring was modified because cerebral failure was not assessed. 4Shock at randomization was defined as a mean arterial pressure of less than 70 mm Hg,
the need for ongoing treatment with vasopressor or inotropic agents, or a plasma lactate level of more than 4.0 mmol per liter in the hour before randomization.
5Acute kidney injury was defined as a renal SOFA score of 2 or higher (plasma creatinine level > 170 μmol/l (1.9 mg/dl) or urinary output < 500 ml/d). 6Chronic
renal disease was defined as a preadmission plasma creatinine > 100 μmol/l (1.2 mg/dl). HES, hydroxyethyl starch; SAPS, simplified acute physiology score; SOFA,
sequential organ failure assessment, COPD, chronic obstructive pulmonary disease.
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There were no statistically significant differences in
the occurrence or severity of pruritus between the two
intervention groups. The point estimates did favor the
Ringer’s group and more patients in the HES group had
used medications against pruritus. That HES may cause
pruritus also in ICU patients is supported by data from





Time to follow-up - months 13 (9-17) 14 (10-18)
Age - years 66 (59-74) 66 (58-75)
Male gender - no. (%) 52 (53) 53 (58)
Included at university hospital - no. (%) 35 (36) 36 (39)
Surgery1 - no. (%)
Emergency 31 (32) 33 (36)
Elective 7 (7) 17 (18)
Source of ICU admittance - no. (%)
Emergency department 32 (33) 21 (23)
General ward 40 (41) 39 (42)
Operating or recovery room 17 (17) 21 (23)
Other ICU in the same hospital 2 (2) 2 (2)
Other hospital 7 (7) 9 (10)
Source of sepsis2 - no. (%)
Lungs 42 (43) 38 (41)
Abdomen 40 (41) 33 (36)
Urinary tract 13 (13) 13 (14)
Soft tissue 9 (9) 14 (15)
Other 10 (10) 12 (13)
Positive culture from blood or a sterile site - no. (%) 17 (17) 11 (12)
Time from ICU admission to randomization - hours 3 (1-11) 3 (1-14)
SAPS II 48 (36-58) 50 (38-59)
SOFA score3 7 (5-9) 7 (5-9)
Shock4 - no. (%) 80 (82) 80 (87)
Acute kidney injury5 - no. (%) 36 (37) 35 (38)
Mechanical ventilation - no. (%) 44 (45) 54 (59)
Comorbidities
Diabetes mellitus - no. (%) 12 (12) 16 (17)
Arterial hypertension - no. (%) 42 (43) 39 (42)
Chronic renal disease6 - no. (%) 9 (10) 14 (17)
Hematological malignancy - no. (%) 6 (6) 9 (10)
Previous admission for - no. (%)
Heart failure or myocardial infarction 10 (10) 12 (13)
Stroke 7 (7) 6 (7)
Asthma or COPD 12 (12) 12 (13)
Any ventilation in the ICU, n (%) 71 (72) 72 (78)
Days in ventilator if treated, median (IQR) 6 (3-14) 5 (3-12)
Any renal replacement therapy dialysis in the ICU, n (%) 18 (18) 15 (16)
Days in renal replacement therapy if treated, median (IQR) 7 (3-22) 10 (6-22)
Days in ICU, median (IQR) 6 (3-14) 8 (4-14)
Days in hospital in the 90 days follow-up period, median (IQR) 32 (20-50) 30 (20-53)
1Numbers are for patients who underwent surgery during the index hospitalization, but before randomization. 2Some patients had more than one source of
infection. The ‘other’ category included sepsis from a vascular catheter-related infection, meningitis, or endocarditis, as well as sepsis from unknown sources. 3The
SOFA scoring was modified because cerebral failure was not assessed. 4Shock at randomization was defined as a mean arterial pressure of less than 70 mm Hg,
the need for ongoing treatment with vasopressor or inotropic agents, or a plasma lactate level of more than 4.0 mmol per liter in the hour before randomization.
5Acute kidney injury was defined as a renal SOFA score of 2 or higher (plasma creatinine level > 170 μmol/l (1.9 mg/dl) or urinary output < 500 ml/d). 6Chronic
renal disease was defined as a preadmission plasma creatinine > 100 μmol/l (1.2 mg/dl). HES, hydroxyethyl starch; SAPS, simplified acute physiology score; SOFA,
sequential organ failure assessment, COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
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the CHEST trial, where HES 130/0.4 doubled the occur-
rence of pruritus compared to saline in general ICU
patients [2]. It is noteworthy that a considerable number
of patients in the Ringer’s group reported pruritus in
our study, suggesting that this is very frequent in survi-
vors of severe sepsis. We observed many more patients
with pruritus than in the CHEST and CRYSTMAS trials
[2,5]. The reasons for these differences may be due to
differences in the timing, methods/questionnaires used
to capture pruritus and to the different HES doses and
patient populations in these trials. There are no details
on the methods for pruritus assessment in the reports
of the CHEST and CRYSTMAS trials.
The PCS and MCS scores observed here are within
the range of those observed in other studies of HRQoL
using SF-36 in long-term survivors of sepsis [16,28].
More importantly, the PCS and MCS scores observed
are well below those in the general population underlin-
ing the importance of HRQoL as an outcome measure
in patients with severe sepsis in general and in trials in
particular. The latter is substantiated by our observation
of differences in HRQoL between patients in the two
intervention groups.
There are several strengths to this study. The risk of
bias was minimized by preparing the analysis plan before
the analyses were done and both patients and the investi-
gator analyzing the data were blinded to the intervention.
Also the intervention groups were comparable at rando-
mization. We used a validated tool to assess HRQoL,
obtained good data quality and the results were compar-
able in the analyses of the imputed and complete-case
datasets.
The study has several limitations. These were post hoc
analyses of the Danish survivors only. We made contact
with patients at the same time point, so that the follow-
up time varied. Only 60% of the survivors responded and
these patients were older and more had shock at baseline
than the nonresponders. We cannot know if any of these
Table 3 Health-related quality of life in patients with severe sepsis allocated to HES 130/0
Imputation dataset Complete case dataset
HES group Ringer’s group HES group Ringer’s group
Scale N IQR N IQR P value N IQR N IQR P -value
Primary outcomes
PCS 88 37 (29-48) 83 40 (32-51) 0.23 74 38 (29-48) 63 42 (33-52) 0.15
MCS 88 45 (36-55) 83 53 (39-60) 0.01 74 46 (35-56) 63 54 (41-59) 0.02
Secondary outcomes
PF 94 50 (20-75) 86 65 (30-85) 0.17 91 50 (20-75) 81 65 (30-85) 0.23
RP 87 0 (0-75) 82 13 (0-75) 0.63 85 0 (0-75) 79 25 (0-75) 0.46
BP 95 52 (31-84) 86 73 (42-100) 0.007 91 52 (31-84) 83 72 (42-100) 0.02
GH 95 42 (30-62) 87 52 (25-72) 0.35 86 41 (30-62) 80 52 (30-72) 0.19
VT 94 45 (29-60) 85 55 (35-75) 0.008 92 45 (28-60) 82 55 (35-75) 0.004
SF 93 75 (38-100) 86 88 (63-100) 0.03 88 75 (38-100) 81 75 (63-100) 0.07
RE 87 33 (0-100) 81 67 (0-100) 0.19 84 33 (0-100) 78 67 (0-100) 0.18
MH 93 64 (52-82) 86 80 (60-92) 0.004 91 64 (52-84) 85 80 (60-92) 0.006
Data from the imputed and complete case datasets are given. Values are medians and interquartile ranges (IQR). N = number of patient where the scales could
be calculated. HES, hydroxyethyl starch; PCS, physical component summary; MCS, mental component summary; PF, physical functioning; RP, role physical; BP,
bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health.
Table 4 Pruritus in patients with severe sepsis allocated to HES 130/0
HES
130/0.42
Ringer’s acetate Relative risk (95%CI) P value
Primary outcome
Pruritus at any time after discharge, n/N (%) 47/96 (49) 38/88 (43) 1.13 (0.83-1.55) 0.43
Secondary outcomes
Pruritus in the last 48 hours, n/N (%) 31/95 (33) 24/89 (27) 1.21 (0.77-1.89) 0.40
VAS score, median (IQR)* 4.5 (3.5-5.5) 3.5 (2.0-6.5) - 0.28
Action taken against pruritus n/N (%) 36/96 (37) 20/88 (23) 1.65 (1.04-2.62) 0.03
Use of ointment/tablets n/N (%) 36/96 (37) 19/88 (21) 1.74 (1.08-2.79) 0.02
Consulted GP n/N (%) 11/96 (11) 7/88 (8) 1.26 (0.53-2.99) 0.60
Consulted dermatologist n/N (%) 2/96 (2) 5/88 (6) 0.37 (0.07-1.84) 0.20
N = number of patients in the treatment group. n = number of cases. *Medians are for those who had pruritus within the last 48 hours. HES, hydroxyethyl starch;
VAS, visual analogue scale; IQR, interquartile range, GP, general practitioner.
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limitations introduced bias. In 10% of the responses not
all the scales were computable. As any missing data
introduce uncertainty, we based our analyses on the cur-
rently recommended statistical approach [29], which is to
impute data rather than to trust the complete-case ana-
lyses. The imputation lowered the number of cases with
missing data to 3%, which likely minimized the potential
bias. In addition, the best/worst-case analysis, which is
the most conservative approach, did not change the
direction of the intervention effect, but only the differ-
ence observed in MH remained significant when the
missing data in the HES group were given the best possi-
ble score and those in the Ringer’s group the worst possi-
ble score. It is unclear which magnitude of difference in
SF-36 scores represents a meaningful difference for
patients [30,31]. Therefore, we cannot know if the
observed differences in HRQoL mattered to the patients.
Finally, our pruritus questionnaire has not been validated
and we observed frequencies of pruritus that were much
higher than those in the other trials of HES in ICU
patients as described above.
Conclusions
Patients with severe sepsis assigned to resuscitation with
HES 130/0.42 had worse self-perceived HRQoL at long-
term follow-up than those who received Ringer’s acetate,
whereas there were no statistically significant differences
in the occurrence of pruritus between the intervention
groups. As these data add to the growing amount of evi-
dence of worse outcome with HES in patients with severe
sepsis, we recommend not using HES for these patients.
Key messages
• The study showed that survivors of severe sepsis
treated with hydroxyethyl starch scored significantly
lower in SF-36 than those treated with Ringer’s solu-
tion. The differences were seen in the mental com-
ponent summary score, and the vitality, mental
health, social function and bodily pain scales.
• The differences in frequency and severity of pruri-
tus between the HES and Ringer’s group were not
statistically significant.
• Pruritus was very frequent in the sepsis survivors
in the present trial.
Additional material
Additional file 1: 6S inclusion and exclusion criteria, best/worst-case
analyses and pruritus questionnaire.
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